Clinical performance of three fully automated anti-SARS-CoV-2 immunoassays targeting the nucleocapsid or spike proteins.
Adult
Aged
Aged, 80 and over
Antibodies, Viral
/ blood
COVID-19
/ blood
COVID-19 Testing
/ methods
Coronavirus Nucleocapsid Proteins
/ blood
Cross Reactions
Enzyme-Linked Immunosorbent Assay
Female
Humans
Immunoassay
/ methods
Immunoglobulin A
/ blood
Immunoglobulin G
/ blood
Male
Middle Aged
Phosphoproteins
/ blood
Retrospective Studies
SARS-CoV-2
/ isolation & purification
Sensitivity and Specificity
Spike Glycoprotein, Coronavirus
/ analysis
COVID-19
SARS-CoV-2
cut-off
serology
symptom onset
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
03
08
2020
revised:
26
10
2020
accepted:
10
11
2020
pubmed:
18
11
2020
medline:
20
3
2021
entrez:
17
11
2020
Statut:
ppublish
Résumé
This study assesses the clinical performance of three anti-SARS-CoV-2 assays, namely EUROIMMUN anti-SARS-CoV-2 nucleocapsid (IgG) ELISA, Elecsys anti-SARS-CoV-2 nucleocapsid (total antibodies) assay, and LIAISON anti-SARS-CoV-2 spike proteins S1 and S2 (IgG) assay. One hundred and thirty-seven coronavirus disease 2019 (COVID-19) samples from 96 reverse-transcription polymerase chain reaction confirmed patients were chosen to perform the sensitivity analysis. Non-SARS-CoV-2 sera (n = 141) with a potential cross-reaction to SARS-CoV-2 immunoassays were included in the specificity analysis. None of these tests demonstrated a sufficiently high clinical sensitivity to diagnose acute infection. Fourteen days since symptom onset, we did not find any significant difference between the three techniques in terms of sensitivities. However, Elecsys performed better in terms of specificity. All three anti-SARS-CoV-2 assays had equivalent sensitivities 14 days from symptom onset to diagnose past-COVID-19 infection. We also confirmed that anti-SARS-CoV-2 determination before Day 14 is of less clinical interest.
Identifiants
pubmed: 33200836
doi: 10.1002/jmv.26669
pmc: PMC7753716
doi:
Substances chimiques
Antibodies, Viral
0
Coronavirus Nucleocapsid Proteins
0
Immunoglobulin A
0
Immunoglobulin G
0
Phosphoproteins
0
Spike Glycoprotein, Coronavirus
0
nucleocapsid phosphoprotein, SARS-CoV-2
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2262-2269Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Clin Chem. 2020 Aug 1;66(8):1107-1109
pubmed: 32484860
Clin Chem Lab Med. 2020 Jun 25;58(7):1156-1159
pubmed: 32301750
J Infect. 2020 Aug;81(2):e91-e92
pubmed: 32417311
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Diagnostics (Basel). 2020 Apr 05;10(4):
pubmed: 32260471
JAMA. 2020 Jun 9;323(22):2245-2246
pubmed: 32391855
N Engl J Med. 2020 Mar 26;382(13):1268-1269
pubmed: 32109011
Clin Chem Lab Med. 2020 Jun 25;58(7):1081-1088
pubmed: 32301749
Br J Haematol. 2020 Aug;190(4):e187-e189
pubmed: 32557555
Clin Chem. 2020 Jul 1;66(7):875-877
pubmed: 32343775
J Med Virol. 2021 Apr;93(4):2262-2269
pubmed: 33200836
Clin Chem Lab Med. 2020 Jun 25;58(7):1070-1076
pubmed: 32172228
Clin Chem. 2020 Aug 1;66(8):1055-1062
pubmed: 32402061
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
Clin Chem Lab Med. 2020 Sep 25;58(10):e193-e196
pubmed: 32639942
Clin Chim Acta. 2020 Oct;509:18-21
pubmed: 32485155
Clin Chem Lab Med. 2020 Jun 25;58(7):1144-1145
pubmed: 32386187
Lancet Infect Dis. 2020 Jul;20(7):758-759
pubmed: 32330441
J Clin Virol. 2020 Jul;128:104413
pubmed: 32403010
Clin Chem Lab Med. 2020 Jul 28;58(8):1357-1364
pubmed: 32447328
Clin Chem. 2020 Aug 1;66(8):1104-1106
pubmed: 32484887
Clin Chim Acta. 2020 Oct;509:1-7
pubmed: 32485157
Clin Biochem. 2020 Dec;86:23-27
pubmed: 32858061
Clin Chem Lab Med. 2020 Jun 25;58(7):1037-1052
pubmed: 32459192
J Med Virol. 2021 Feb;93(2):803-811
pubmed: 32667733